The acquisition gave BMS control of Karuna’s lead asset, KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism ...

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Zai Lab (NASDAQ:ZLAB) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.78 and the consensus Revenue Estimate is $102.24M ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

or KarXT. This news “may also prove to be a substantial positive” for Neurocrine (NBIX) “if – and it’s admittedly a huge IF – the company can successfully navigate” its own pending Phase 3 program, ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Earlier this year, BMY completed a $14 billion acquisition of Karuna Therapeutics, gaining access to its experimental ...